论文部分内容阅读
目的比较ＧＰ（健择＋ＤＤＰ）与ＦＬＥＰ（ＣＦ、５－Ｆｕ、ＥＰＩ、ＤＤＰ）方案治疗晚期胰腺癌的近期疗效与不良反应。方法将４０例晚期胰腺癌随机分为治疗组和对照组，分别给予ＧＰ与ＦＬＥＰ方案化疗２个周期，按ＷＨＯ标准评定疗效和不良反应。结果两组有效率（ＣＲ＋ＰＲ）分别为３０％和１５％，治疗组高于对照组（Ｐ＜０．０５），两组的毒副反应相似。不良反应主要为骨髓抑制和胃肠道反应。结论健择加顺铂是治疗晚期胰腺癌的一种安全有效的化疗方案。
Objective To compare the short-term effects and side effects of GP (Gemcitabine + DDP) and FLEP (CF, 5-Fu, EPI, DDP) regimen in the treatment of advanced pancreatic cancer. Methods Forty patients with advanced pancreatic cancer were randomly divided into treatment group and control group. Two cycles of GP and FLEP regimen were given respectively. Efficacy and adverse reactions were evaluated according to WHO criteria. Results The effective rates (CR + PR) of the two groups were 30% and 15% respectively, which were significantly higher in the treatment group than those in the control group (P <0.05). The toxicity of the two groups was similar. Adverse reactions are mainly myelosuppression and gastrointestinal reactions. Conclusions Gemcitabine plus cisplatin is a safe and effective chemotherapy for advanced pancreatic cancer.